Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports First Quarter 2017 Financial Results
Ligand to Report First Quarter 2017 Results on May 9th
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology
Ligand to Participate in Upcoming Investor Conference
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene
Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform
Reminder: Ligand to Host Analyst Day on February 28th in New York City
Ligand to Host Analyst Day on February 28th in New York City
